Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isuzinaxib (AptaBio Therapeutics Inc.)
- Development stage
- Unknown
- Lead developer
- Aptabio Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Isuzinaxib (APX-115) is an orally active, first-in-class pan-NADPH oxidase (NOX) inhibitor developed by AptaBio. It targets multiple NOX isozymes, specifically NOX1, NOX2, and NOX4, to suppress the overproduction of reactive oxygen species (ROS) and regulate oxidative stress. By inhibiting NOX-mediated ROS generation, isuzinaxib reduces inflammation and fibrosis, showing therapeutic potential in diabetic kidney disease (diabetic nephropathy), contrast-induced acute kidney injury, and non-alcoholic steatohepatitis (NASH).
- Other names
- isuzinaxib hydrochloride
02
Targets
NOX1 (NADPH oxidase 1)NOX2 (NADPH oxidase 2)NOX4 (NADPH oxidase 4)
Beyond the preview
Go deeper on isuzinaxib (AptaBio Therapeutics Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isuzinaxib (AptaBio Therapeutics Inc.).